<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-06T11:56:27Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/6253" metadataPrefix="oai_dc">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/6253</identifier><datestamp>2024-07-25T07:33:04Z</datestamp><setSpec>com_10259_4363</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>com_10259_4365</setSpec><setSpec>com_10259_6256</setSpec><setSpec>com_10259_9476</setSpec><setSpec>com_10259.4_106</setSpec><setSpec>col_10259_9477</setSpec><setSpec>col_10259_4366</setSpec><setSpec>col_10259_6257</setSpec><setSpec>col_10259_4364</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>Distinct mechanism of action for antitumoral neutral cyclometalated Pt(II)-complexes bearing antifungal imidazolyl-based drugs</dc:title>
<dc:creator>Fernández Pampín, Natalia</dc:creator>
<dc:creator>Vaquero Gutiérrez, Mónica</dc:creator>
<dc:creator>Gil Antón, Tania</dc:creator>
<dc:creator>Espino Ordóñez, Gustavo</dc:creator>
<dc:creator>Fernández Zoppino, Darío</dc:creator>
<dc:creator>García Ruiz, Begoña</dc:creator>
<dc:creator>Busto Vázquez, Natalia</dc:creator>
<dc:subject>Cyclometalated platinum(II) complexes</dc:subject>
<dc:subject>Clotrimazole</dc:subject>
<dc:subject>Bifonazole</dc:subject>
<dc:subject>Reactive oxygen species (ROS)</dc:subject>
<dc:subject>Antitumoral</dc:subject>
<dc:subject>Química inorgánica</dc:subject>
<dc:subject>Bioquímica</dc:subject>
<dc:subject>Chemistry, Inorganic</dc:subject>
<dc:subject>Biochemistry</dc:subject>
<dc:description>Three neutral Pt(II) complexes containing 1-Methylimidazole and the antifungal imidazolyl drugs Clotrimazole and Bifonazole have been prepared. The general formula of the new derivatives is [Pt(κ2-(C^N)Cl(L)], where C^N stands for ppy = 2-phenylpyridinate, and L = 1-Methylimidazole (MeIm) for [Pt-MeIm]; L = Clotrimazole (CTZ) for [Pt-CTZ] and L = Bifonazole (BFZ) for [Pt-BFZ]). The complexes have been completely characterized in solution and the crystal structures of [Pt-BFZ] and [Pt-CTZ] have been resolved. Complexes [Pt-MeIm] and [Pt-BFZ] present higher cytotoxicity than cisplatin in SW480 (colon adenocarcinoma), A549 (lung adenocarcinoma) and A2780 (ovarian cancer) cell lines. [Pt-MeIm] shows the highest accumulation in A549 cells, in agreement with its inability to interact with serum albumin. By contrast, [Pt-CTZ] and [Pt-BFZ] interact with serum proteins, a fact that reduces their bioavailability. The strongest interaction with bovine serum albumin (BSA) is found for [Pt-BFZ], which is the least internalized inside the cells. All the complexes are able to covalently interact with DNA. The most cytotoxic complexes, [Pt-MeIm] and [Pt-BFZ] induce cellular accumulation in G0/G1 and apoptosis by a similar pathway, probably involving a reactive oxygen species (ROS) generation mechanism. [Pt-BFZ] turns out to be the most efficient complex regarding ROS generation and causes mitochondrial membrane depolarization, whereas [Pt-MeIm] induces the opposite effect, hyperpolarization of the mitochondrial membrane. On the contrary, the least cytotoxic complex, [Pt-CTZ] cannot block the cell cycle or generate ROS and the mechanism by which it induces apoptosis could be a different one.</dc:description>
<dc:description>La Caixa Foundation (LCF/PR/PR12/11070003), Consejería de Educación-Junta de Castilla y León-FEDER (BU042U16-BU305P18), Ministerio de Ciencia, Innovación y Universidades (RTI2018-102040-B-100). M.V. is grateful for the financial support received from the Consejería de Educación-Junta de Castilla y León-FEDER (BU042U16-BU305P18).</dc:description>
<dc:date>2021-12-02T09:29:29Z</dc:date>
<dc:date>2021-12-02T09:29:29Z</dc:date>
<dc:date>2022-01</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:identifier>0162-0134</dc:identifier>
<dc:identifier>http://hdl.handle.net/10259/6253</dc:identifier>
<dc:identifier>10.1016/j.jinorgbio.2021.111663</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Journal of Inorganic Biochemistry. 2022, V. 226, 111663</dc:relation>
<dc:relation>https://doi.org/10.1016/j.jinorgbio.2021.111663</dc:relation>
<dc:relation>info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-102040-B-I00/ES/PROPIEDADES ANTIMICROBIANAS DE NUEVOS COMPLEJOS ORGANOMETALICOS</dc:relation>
<dc:relation>info:eu-repo/grantAgreement/Junta de Castilla y León//BU042U16</dc:relation>
<dc:relation>info:eu-repo/grantAgreement/Junta de Castilla y León//BU305P18</dc:relation>
<dc:relation>info:eu-repo/grantAgreement/Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona//LCF%2FPR%2FPR12%2F11070003</dc:relation>
<dc:rights>Atribución 4.0 Internacional</dc:rights>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:publisher>Elsevier</dc:publisher>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>